SG11201808809PA - Therapeutic hpv vaccine combinations - Google Patents

Therapeutic hpv vaccine combinations

Info

Publication number
SG11201808809PA
SG11201808809PA SG11201808809PA SG11201808809PA SG11201808809PA SG 11201808809P A SG11201808809P A SG 11201808809PA SG 11201808809P A SG11201808809P A SG 11201808809PA SG 11201808809P A SG11201808809P A SG 11201808809PA SG 11201808809P A SG11201808809P A SG 11201808809PA
Authority
SG
Singapore
Prior art keywords
international
archimedesweg
kda
prevention
janssen
Prior art date
Application number
SG11201808809PA
Inventor
Jerome Custers
Gerrit C Scheper
Selina Khan
Evelien M Bunnik
Markus Kalla
Katrin Weidner
Original Assignee
Janssen Vaccine & Prevention B V
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccine & Prevention B V, Bavarian Nordic As filed Critical Janssen Vaccine & Prevention B V
Publication of SG11201808809PA publication Critical patent/SG11201808809PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 011101011M HO 11111 0 I 01111101010111110111110111011 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/192418 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: (NL). KHAN, Selina; c/o Janssen Vaccines & Prevention A61K 39/12 (2006.01) C07K 14/025 (2006.01) B.V., Archimedesweg 4, 2333 CN Leiden (NL). KALLA, (21) International Application Number: Markus; Wolfl 6c, 823777 Penzberg (DE). WEIDNER, PCT/US2017/030338 Katrin; Lessingstrasse 6c, 93049 Regensburg (DE). (22) International Filing Date: (74) Agent: SIMS, Sara E. et al.; Panitch Schwarze Belisario 01 May 2017 (01.05.2017) & Nadel LLP, One Commerce Square, 2005 Market Street, Suite 2200, Philadelphia, PA 19103 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/330,562 02 May 2016 (02.05.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/447,094 17 January 2017 (17.01.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (71) Applicants: JANSSEN VACCINE & PREVENTION KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, B.V. [NL/NL]; Archimedesweg 4, NL-2333 CN Leiden MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (NL). BAVARIAN NORDIC A/S [DK/DK]; Hejreskowej PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 10A, DK-3490 Kvistgaard (DK). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (72) Inventor; and TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for US only): BUNNIK, Evelien M. [NL/US]; (84) Designated States (unless otherwise indicated, for every _ 1105 County Road 2720, Mico, TX 78056 (US). kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: CUSTERS, Jerome, H.h.v.; c/o Janssen Vac- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = cines & Prevention B.V., Archimedesweg 4, 2333 CN Lei-TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, den (NL). SCHEPER, Gerrit C.; c/o Janssen Vaccines — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = & Prevention B.V., Archimedesweg 4, 2333 CN Leiden (54) Title: THERAPEUTIC HPV = _ = — <c.• = 100 kDa — = 75 kDa — = = = 50 kDa — = 37 kDa — = 1-1 GC 11 7r c ei 1-1 IN 1-1 0 ei • 2' (e, , A G ' ( t, , VACCINE COMBINATIONS (57) : Vectors, vaccines, vaccine compositions and vaccine combinations for use as therapeutics against HPV18 and/or HPV16 are described. Ne Anti-H PV16 E7 Anti NF-kB Fig. 1 C [Continued on next page] WO 2017/192418 Al MIDEDIM01101 DIDIRMEM300101111111111111101111111111111111111 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
SG11201808809PA 2016-05-02 2017-05-01 Therapeutic hpv vaccine combinations SG11201808809PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330562P 2016-05-02 2016-05-02
US201762447094P 2017-01-17 2017-01-17
PCT/US2017/030338 WO2017192418A1 (en) 2016-05-02 2017-05-01 Therapeutic hpv vaccine combinations

Publications (1)

Publication Number Publication Date
SG11201808809PA true SG11201808809PA (en) 2018-11-29

Family

ID=59215960

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808809PA SG11201808809PA (en) 2016-05-02 2017-05-01 Therapeutic hpv vaccine combinations

Country Status (12)

Country Link
US (1) US10517944B2 (en)
EP (1) EP3452087A1 (en)
JP (1) JP7053491B2 (en)
CN (1) CN109922829A (en)
AU (1) AU2017259259B2 (en)
BR (1) BR112018072372A2 (en)
CA (1) CA3021341A1 (en)
IL (1) IL262731A (en)
MX (1) MX2018013340A (en)
SG (1) SG11201808809PA (en)
WO (1) WO2017192418A1 (en)
ZA (1) ZA201808121B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58080B1 (en) * 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
US20230405105A1 (en) 2019-09-20 2023-12-21 Transgene Sa Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody
AU2021233167A1 (en) 2020-03-12 2022-09-22 Bavarian Nordic A/S Compositions improving poxvirus stability
US20210315986A1 (en) * 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CN112138150A (en) * 2020-11-26 2020-12-29 怡道生物科技(苏州)有限公司 Therapeutic HPV vaccine based on chimpanzee adenovirus vector, preparation method and application thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
JP3816518B2 (en) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DK0833934T4 (en) 1995-06-15 2012-11-19 Crucell Holland Bv Packaging systems for human recombinant adenovirus for use in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
DE60045138D1 (en) 1999-05-17 2010-12-02 Crucell Holland Bv Recombinant adenovirus of the Ad26 serotype
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (en) 1999-06-03 2003-10-17 Biovector Therapeutics POLYEPITOPIC PROTEIN FRAGMENTS, THEIR OBTAINMENT AND THEIR USES IN PARTICULAR IN VACCINATION
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
US6733994B2 (en) 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
CN101676389A (en) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 Modified vaccinia ankara virus variant
CA2446110C (en) 2001-05-01 2013-06-25 National Research Council Of Canada A system for inducible expression in eukaryotic cells
ATE447037T1 (en) 2002-04-25 2009-11-15 Crucell Holland Bv MEANS AND METHOD FOR PRODUCING ADENOVIRUS VECTORS
AU2003236646B2 (en) 2002-05-16 2009-01-15 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP1718738A2 (en) 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
JP5291341B2 (en) 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー Selection of host cells that express proteins at high levels
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
PL1996238T3 (en) 2006-02-28 2016-12-30 Chimeric Adenoviral Vectors and dsRNA as TLR3 Agonist
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
BRPI0810305A2 (en) * 2007-05-15 2018-07-10 Transgene Sa "vector, substantially isolated nucleic acid molecule, host cell, pharmaceutical composition, use of a nucleic acid molecule, use of a vector, use of a host cell, and use of a composition"
DE102008010954A1 (en) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA vaccine for the therapy and prophylaxis of cervical cancer and its premalignant precursors
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
SG11201503200PA (en) * 2012-10-28 2015-05-28 Bavarian Nordic As Pr13.5 promoter for robust t-cell and antibody responses
MY193417A (en) * 2014-09-03 2022-10-12 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
RS58080B1 (en) * 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
BR112018003019A2 (en) 2015-08-20 2018-09-25 Janssen Vaccines & Prevention Bv hpv18 therapeutic vaccines

Also Published As

Publication number Publication date
US20190142933A1 (en) 2019-05-16
JP7053491B2 (en) 2022-04-12
IL262731A (en) 2018-12-31
WO2017192418A8 (en) 2019-05-23
JP2019514943A (en) 2019-06-06
AU2017259259B2 (en) 2020-11-19
MX2018013340A (en) 2019-08-21
WO2017192418A1 (en) 2017-11-09
AU2017259259A1 (en) 2018-11-01
ZA201808121B (en) 2021-05-26
EP3452087A1 (en) 2019-03-13
CA3021341A1 (en) 2017-11-09
BR112018072372A2 (en) 2019-02-19
CN109922829A (en) 2019-06-21
US10517944B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
SG11201808809PA (en) Therapeutic hpv vaccine combinations
SG11201811432WA (en) Rna for cancer therapy
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201805229YA (en) Means and methods for treating hbv
SG11201810210UA (en) Engineered botulinum neurotoxins
SG11201809643UA (en) Compositions and methods of treating huntington&#39;s disease
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804496UA (en) Recombinant zika vaccines
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201903042VA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201808949SA (en) Combinations and methods comprising a capsid assembly inhibitor
SG11201806853VA (en) Abstracted graphs from social relationship graph
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy